Predictive Role of Acute Phase Reactants in the Response to Therapy in Patients with Chronic Hepatitis C Virus Infection

Basit Öğe Kaydı
dc.contributor.authorOguz, Ayten
dc.contributor.authorAtay, Ahmet Engin
dc.contributor.authorTas, Adnan
dc.contributor.authorSeven, Gulseren
dc.contributor.authorKoruk, Mehmet
dc.date.accessioned2024-04-24T17:24:49Z
dc.date.available2024-04-24T17:24:49Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Aims: Biochemical parameters and acute-phase proteins (APPs) may provide complementary data in patients with chronic hepatitis C (CHC). We aimed to evaluate the predictive role of APPs in the response to antiviral therapy. Methods: Forty-five patients underwent antiviral therapy. Serum ferritin, C-reactive protein (CRP), transferrin, albumin, alpha-1 acid glycoprotein (A1AG), and alpha-2 macroglobulin (A2MG) levels were examined at the initial evaluation and at the 4th, 12th, and 48th weeks. HCV RNA levels were examined at the initial evaluation and at the 12th and 48th weeks. Results: Ferritin, transferrin, A1AG, and A2MG levels were significantly higher in the patient group (p<0.05). CRP, ferritin, A1AG, and A2MG levels were significantly increased from baseline to the 4th week (p<0.05). The responders and nonresponders to antiviral therapy had insignificantly but remarkably different levels of CRP, ferritin, transferrin, A1AG, A2MG, and alanine aminotransferase (ALT) both at the initial evaluation and at the 12th week. Conclusions: Variations in ferritin, A1AG, A2MG, albumin, CRP, and transferrin levels are not alternatives to virological and biochemical parameters for predicting an early response to therapy in patients with CHC. However, the investigation of ALT levels and hepatitis C virus RNA in combination with acute-phase reactants may provide supplementary data for evaluating responses to antiviral therapy. (Gut Liver 2013;7:82-88)en_US
dc.identifier.doi10.5009/gnl.2013.7.1.82
dc.identifier.endpage88en_US
dc.identifier.issn1976-2283
dc.identifier.issn2005-1212
dc.identifier.issue1en_US
dc.identifier.pmid23424009
dc.identifier.scopus2-s2.0-84875085915
dc.identifier.scopusqualityQ1
dc.identifier.startpage82en_US
dc.identifier.urihttps://doi.org/10.5009/gnl.2013.7.1.82
dc.identifier.urihttps://hdl.handle.net/11468/19846
dc.identifier.volume7en_US
dc.identifier.wosWOS:000313775600012
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherEditorial Office Gut & Liveren_US
dc.relation.ispartofGut and Liver
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis Cen_US
dc.subjectAcute-Phase Proteinsen_US
dc.subjectHepatitis C Virus Rnaen_US
dc.titlePredictive Role of Acute Phase Reactants in the Response to Therapy in Patients with Chronic Hepatitis C Virus Infectionen_US
dc.titlePredictive Role of Acute Phase Reactants in the Response to Therapy in Patients with Chronic Hepatitis C Virus Infection
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu